Modalis Therapeutics Corp

Modalis Therapeutics Corp has a strong liquidity position, with cash and equivalents amounting to ¥2.81 billion, representing 97% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative capital structure. The current ratio of 21.46 suggests a high ability to meet short-term obligations. The company is currently unprofitable, with a net loss of ¥2.15 billion and an operating loss of ¥221.4 million. Return on equity and return on assets are both negative, at -77.07% and -72.62%, respectively, indicating poor capital efficiency and profitability. These metrics fall significantly below the industry median for biotechnology firms, which typically report positive returns during periods of R&D investment. Modalis operates two business models: a collaborative model with five pipeline items such as MDL-201, and an in-house model with two pipeline items such as MDL-101. The company does not disclose geographic revenue concentration, but as a Japan-based firm, it is likely concentrated in the Asia-Pacific region. No major international revenue streams are reported. The company has no reported revenue and is experiencing negative operating cash flow of ¥2.12 billion. Outlook data is not available for the next fiscal year, but the company is expected to continue incurring losses as it advances its gene therapy pipeline. The absence of revenue and ongoing R&D costs suggest a long-term growth trajectory dependent on successful clinical trials and commercialization. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no dilution pressure in the near term, as shares outstanding remain unchanged between basic and diluted measures. No recent equity issuance or ATM/shelf registration is reported. Recent financial filings and transcripts do not indicate any material events or strategic shifts. The company remains focused on its CRISPR-GNDM platform and pipeline development. No significant regulatory or legal events have been disclosed in the latest filings.